324 related articles for article (PubMed ID: 30972265)
1. Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review.
Maqsood MH; Tameez Ud Din A; Khan AH
Cureus; 2019 Jan; 11(1):e3986. PubMed ID: 30972265
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.
Boucher JE; Sommers R
Clin J Oncol Nurs; 2018 Oct; 22(5):565-568. PubMed ID: 30239510
[TBL] [Abstract][Full Text] [Related]
3. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Efficacy, Survival, and Safety of [
Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
[No Abstract] [Full Text] [Related]
5. Long-term clinical outcomes of [
Iqbal S; Zhuang E; Raj M; Bahary N; Monga DK
Front Oncol; 2024; 14():1393317. PubMed ID: 38817893
[TBL] [Abstract][Full Text] [Related]
6. Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors.
McClellan K; Chen EY; Kardosh A; Lopez CD; Del Rivero J; Mallak N; Rocha FG; Koethe Y; Pommier R; Mittra E; Pegna GJ
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230691
[TBL] [Abstract][Full Text] [Related]
7. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
Am J Clin Oncol; 2022 Jun; 45(6):233-242. PubMed ID: 35507413
[TBL] [Abstract][Full Text] [Related]
8. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
9. Radionuclide Therapy for Neuroendocrine Tumors.
Cives M; Strosberg J
Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
[TBL] [Abstract][Full Text] [Related]
10. A Clinical Guide to Peptide Receptor Radionuclide Therapy with
Becx MN; Minczeles NS; Brabander T; de Herder WW; Nonnekens J; Hofland J
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497273
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of lutetium (
Palmer J; Leeuwenkamp OR
World J Clin Cases; 2020 Oct; 8(20):4793-4806. PubMed ID: 33195647
[TBL] [Abstract][Full Text] [Related]
12. Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review.
Stolniceanu CR; Nistor I; Bilha SC; Constantin V; Simona V; Matovic M; Stefanescu C; Covic A
Nucl Med Commun; 2020 Jul; 41(7):601-617. PubMed ID: 32404645
[TBL] [Abstract][Full Text] [Related]
13. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
14. Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients.
Strosberg JR; Al-Toubah T; El-Haddad G; Reidy Lagunes D; Bodei L
J Nucl Med; 2024 Mar; 65(3):340-348. PubMed ID: 38238038
[TBL] [Abstract][Full Text] [Related]
15. Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids.
Naraev BG; Ramirez RA; Kendi AT; Halfdanarson TR
Clin Lung Cancer; 2019 May; 20(3):e376-e392. PubMed ID: 30910575
[TBL] [Abstract][Full Text] [Related]
16. Lutetium Lu-177 Dotatate Flare Reaction.
Salner AL; Blankenship B; Dunnack H; Niemann C; Bertsch H
Adv Radiat Oncol; 2021; 6(1):100623. PubMed ID: 33490736
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors.
Das S; Dasari A
Ther Adv Med Oncol; 2021; 13():17588359211018047. PubMed ID: 34093744
[TBL] [Abstract][Full Text] [Related]
18. A Care Process Model to Deliver
Kasi PM; Maige CL; Shahjehan F; Rodgers JM; Aloszka DL; Ritter A; Andrus ML; Mcmillan JM; Mody K; Sharma A; Jain MK
Front Oncol; 2018; 8():663. PubMed ID: 30687638
[No Abstract] [Full Text] [Related]
19. Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review.
Camus B; Cottereau AS; Palmieri LJ; Dermine S; Tenenbaum F; Brezault C; Coriat R
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33803817
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
